LRRK2 and Parkinson disease: In contrast to effects observed in urine, BMP(22:6/22:6) levels were reduced by 36% (unadjusted p = 0.01) in CSF from PD patients that carry a LRRK2 variant relative to the PD patients without LRRK2 variants (Fig. 7A and B).